Overview
Atrial fibrillation is a highly prevalent and incidental arrhythmia, often asymptomatic, and frequently detected incidentally or in association with a stroke. Subclinical atrial fibrillation increases cardioembolic risk, highlighting the need for timely diagnosis.
New wireless devices capable of recording heart rhythm, combined with innovative artificial intelligence tools, could be useful in the prediction and detection of this arrhythmia.
Objective: to determine the usefulness of home blood pressure and heart rhythm monitoring strategy in the detection of subclinical atrial fibrillation.
Methods: observational, cohort, prospective, multicenter study involving 25 researchers from six Latin American countries. Home blood pressure monitoring and single-lead electrocardiogram recording were performed in a population at moderate to high risk of developing atrial fibrillation. A minimum of twenty 30-second electrocardiographic and blood pressure recordings over 7 days using an Omron Complete Hem-7530 T ECG device will be uploaded from a mobile phone app and then sent to a database for analysis.
Conclusions: the results of this study can provide a simple and accessible home monitoring system for detecting subclinical atrial fibrillation and for optimizing the predictive capacity of arrhythmia risk scores through deep learning.
Description
The BP/AF Mode study is a multicenter, observational, prospective, cohort trial involving 25 researchers from six countries: Argentina, Chile, Colombia, Ecuador, Mexico, and Peru. The study was submitted to the IASC Academia (Inter-American Society of Cardiology) and approved under Project File Number 052, dated January 29, 2025. It will be conducted in full compliance with the World Medical Association Codes of Ethics for experiments involving human subjects.
The study aims to include hypertensive patients with no history of atrial fibrillation who are at moderate or high risk of suffering from this arrhythmia according to the HARMS2-AF score or the modified Taiwan AF . The diagnosis of hypertension is supported on the 2023 European Society of Hypertension Guidelines. The patients' baseline characteristics are entered into an interactive web platform, and after that the practitioners received information about cardiovascular risk (Hearts score, Score-2 and Score-OP), Frailty index and atrial fibrillation risk (HARMS2-AF score and modified Taiwan AF score).
After the screening visit, if the patient meets all the inclusion criteria and does not present exclusion criteria, he or she is included in the study and a Omron Complete Hem-7530 T ECG device (Omron Healthcare Co., Ltd., Japan) device is delivered.
The 30-second home ECG tracings will be obtained using the Omron Complete Hem-7530 T ECG
device (Omron Healthcare Co., Ltd., Japan). The connection and smartphone app download
will be available from Omron Connect free of charge on the Google Play Store:
https://play.google.com/store/apps/details?id=jp.co.omron.healthcare.omron_connect&hl=es_
419&pli=1 and on the iOS App Store:
https://apps.apple.com/mx/app/omron-connect/id1003177043. Two duplicate ECG recordings
will be required daily: the first in the morning before breakfast and taking the
prescribed medication, and another in the evening before dinner and taking the
afternoon/evening medication. Additional ECG recordings will be required if the patient
experiences any symptoms. The study investigator will work with the patient to download
the app and perform the first electrocardiogram tracing and transmit it to the database.
The patient will be given instructions on how to correctly perform the ECG and transmit
it to the platform, along with a patient diary. Simultaneously with obtaining the ECG
tracings, the patient will take two BP measurements, in a seated position, separated by
one minute, following the recommendations of the Latin American Society of Hypertension
guidelines. After 1 week, the patient will return the device to the research center. A
recording will be considered valid when at least 80% of the ECG tracings and BP
measurements are valid.
Statistical analysis Considering those patients with a modified Taiwan AF score > 5 points, whose annual incidence of atrial fibrillation ranges between 1.54% and 6.98%, or a HARMS2-AF score > 7 points, whose annual incidence of atrial fibrillation ranges between 1.35% and 6.62%, it will be required to include 499 patients to achieve a 5% margin of error, with a 99% confidence level. If the sample calculation does not achieve the expected results, recruitment will continue until 25 cases of atrial fibrillation are reached.
Continuous variables will be reported as means with their standard deviations for normally distributed variables, or median and interquartile range for non-normally distributed variables. Discrete variables will be reported as absolute values and percentages. Unpaired ANOVA will be used to analyze normally distributed variables, while the Kruskal-Wallis test will be used for non-normally distributed variables. Differences in proportions will be assessed using the Chi-square test. A two-tailed p-value < 0.05 will be considered statistically significant.
Eligibility
Inclusion Criteria:
- 1. Hypertensive patients of both sexes over 75 years of age. 2. Hypertensive
patients between 65 and 75 years of age are associated with one of the following
risk factors:
- Obesity
- Type 2 diabetes
- Obstructive sleep apnea syndrome
- Electrocardiogram showing left ventricular hypertrophy.
- Left ventricular hypertrophy on echocardiogram.
- Left atrial dilation.
- Coronary artery disease
- Chronic kidney disease
- Heart failure with ejection fraction > 50%
- Alcohol intake
- Frequent supraventricular ectopic beats
Exclusion Criteria:
- 1. History of any type of atrial fibrillation. 2. Receiving pharmacological treatments with potential impact on heart rhythm. 3. History of potentially malignant ventricular arrhythmias. 4. Uncontrolled hypothyroidism or hyperthyroidism. 5. Significant chronic obstructive pulmonary disease.